Electromagnetic Resonance Therapy for Autoimmune Diseases

(QSIT Trial)

This trial tests a new therapy called low-frequency electromagnetic resonance (LF-EMR) to determine its effectiveness for autoimmune diseases like lupus, rheumatoid arthritis, or multiple sclerosis. The goal is to see if this therapy can reduce flare-ups and lessen symptoms by improving immune cell communication. Participants will receive either the active therapy or a placebo (inactive treatment) three times a week for twelve weeks. This trial may suit those who have had an autoimmune condition for at least a year and are stable on their current medication. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.

No, you will not have to stop taking your current medications. The trial requires participants to maintain their current medication schedule throughout the study.

Studies suggest that low-frequency electromagnetic resonance (LF-EMR) therapy might help reduce inflammation, benefiting people with autoimmune diseases. Research has shown that similar treatments can lessen inflammation and pain in conditions like rheumatoid arthritis.

Researchers are excited about low-frequency electromagnetic resonance therapy (LF-EMR) for autoimmune diseases because it offers a non-invasive alternative to current treatments like immunosuppressive drugs and biologics, which can have significant side effects. Unlike these conventional treatments, LF-EMR uses resonant fields to promote synchronized signaling among immune cells, potentially reducing flare-ups without altering the immune system broadly. This therapy's unique mechanism targets immune cell communication directly, offering a novel approach that could complement or even replace existing therapies while minimizing side effects.

Research has shown that low-frequency electromagnetic resonance (LF-EMR) therapy might help manage autoimmune diseases. In this trial, participants in the experimental arm will receive active LF-EMR therapy, which studies indicate can affect immune cell communication and reduce inflammation. Evidence suggests that LF-EMR could decrease the frequency and severity of flare-ups in conditions like lupus, rheumatoid arthritis, and multiple sclerosis. Specifically, previous patients have reported improved function and fewer symptoms such as pain and swelling. Overall, this treatment appears promising in controlling immune activity and providing relief for autoimmune conditions.¹⁵⁶⁷⁸